Patents by Inventor Toshinaga Tsuji

Toshinaga Tsuji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized PcrV antibody having anti-pseudomonal activity
    Patent number: 9085611
    Abstract: Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: July 21, 2015
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yoshinori Yamano, Yoshito Numata, Takafumi Sato, Toshinaga Tsuji, Keiko Kawamoto
  • Antibody against PcrV
    Patent number: 8501179
    Abstract: Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: August 6, 2013
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yoshito Numata, Yoshinori Yamano, Takafumi Sato, Toshinaga Tsuji
  • HUMANIZED PCRV ANTIBODY HAVING ANTI-PSEUDOMONAL ACTIVITY
    Publication number: 20120093808
    Abstract: Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV.
    Type: Application
    Filed: March 9, 2010
    Publication date: April 19, 2012
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshinori Yamano, Yoshito Numata, Takafumi Sato, Toshinaga Tsuji, Keiko Kawamoto
  • Antibody against PCRV
    Publication number: 20110150896
    Abstract: Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.
    Type: Application
    Filed: January 8, 2009
    Publication date: June 23, 2011
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshito Numata, Yoshinori Yamano, Takafumi Sato, Toshinaga Tsuji